15289-s-bos

132 | Chapter 8 Table 8.5 | Associations between protein biomarkers, treatment and disease progression HR LCL 95% UCL 95% P 2 AUC for CAD (CI) RR lowering drugs alone 5.04 2.18 11.7 <0 .001 0.783 (0.668-0.897 ) Blood thinner drugs alone <0.001 LRG1 RR lowering drugs Protein/drug interaction ITIH3 RR lowering drugs Protein/drug interaction 0.188 18.9 0.005 0.555 11.1 0.044 0.053 2.12 0.0001 0.207 2.86 0.005 0.668 168 0.221 1.48 43.0 0.405 0.01 0.008 0.006 0.241 <0.001 0.006 0.907(0.818-0.960) 0.783 (0.682-0.899) 0.778 (0.688-0.868) 0.783 (0.682-0.899) C4B RR lowering drugs Protein/drug interaction 0.027 9.34 0.000 0.002 2.04 0.0001 0.464 43.0 0.001 0.013 0.004 0.001 0.916 (0.837-0.961) 0.783 (0.645-0.884) C1QB RR lowering drugs Protein/drug interaction 0.135 13.1 0.000 0.03 2.18 0.0001 0.608 79.1 0.048 0.009 0.005 0.001 0.902 (0.815-0.974) 0.783 (0.657-0.884) CD14 RR lowering drugs Protein/drug interaction 0.258 4.73 0.522 0.072 1.87 0.028 0.923 12.0 9.70 0.037 0.001 0.663 0.658 (0.605-0.763) 0.783 (0.682-0.896) HRG RR lowering drugs 0.235 5.51 0.063 1.78 0.879 17.1 0.031 0.003 0.920 (0.846-0.974) 0.783 (0.668-0.884) Protein/drug interaction 0.316 0.033 3.001 0.316 P: p value for likelihood ratio test that HR=0, LRG1: Leucine-rich alpha-2-glycoprotein, ITIH3: Inter-alpha- trypsin inhibitor heavy chain H3, C4B: Complement C4-B, C1QB: Complement C1q subcomponent subunit B, CD14: Monocyte differentiation antigen, HRG: Histidine-rich glycoprotein Discussion Using highly sensitive proteomic techniques, the present study has revealed six plasma proteins that were significantly associated with coronary artery disease progression in statin-treated FH patients. This is the first study to describe such an association and the findings may represent a novel tool for predicting the development of CAD or the residual CAD risk, independent of classical risk factors and clinical indicators, in this high-risk population. Atherosclerotic cardiovascular disease (CVD) is a leading cause of morbidity and mortality globally. 30 A recent study has shown that proteomic profiling identified both single and multiple marker protein panels that were associated with new-